Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 17;20(18):4590. doi: 10.3390/ijms20184590

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Workflow and FACS analysis of DC/DC_leu generated with Pici-_PGE1 compared to control from leukemic PBMCs in a case of AML. 3–4 × 10⁶ PBMCs were cultured in 12-multiwell-tissue-culure-plates and diluted in 2 mL serum-free X-vivo-15-medium. For the generation of DC/DC_leu with Pici-_PGE1 500 U/mL GM-CSF and 250 U/mL IL-4 were added on day 0. After 6–7 days, 10µg/mL Picibanil a lysis product from Streptococcus pyogenes, which has unspecific immune modulatory effects and 1 µg/mL PGE₁ were added. No response modifiers were added to the control culture. Cells were harvested after 7–10 days of incubation. Half medium exchange was carried out after 3–4 days. x-axis: CD80; y-axis: CD34.